Sriya Bhattacharyya, PhD, Aaron S. Breslow, PhD, Jianee Carrasco, and Benjamin Cook, PhD, MPH
Force is codified in law, so force utilization inequity demands that we consider connections between systemic oppression and individuals’ responses in clinical settings.
AMA J Ethics. 2021;23(4):E340-348. doi:
10.1001/amajethics.2021.340.
Eleftherios Mylonakis, MD and Panayiotis D. Ziakas, MD, MSc, PhD
Allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh antimicrobial stewardship interventions’ risks and benefits.
AMA J Ethics. 2021;23(8):E631-638. doi:
10.1001/amajethics.2021.631.
A history of device oversight by the US Food and Drug Administration traces regulatory changes in response to injuries caused by Dalkon Shield intrauterine devices.
AMA J Ethics. 2021;23(9):E712-720. doi:
10.1001/amajethics.2021.712.
Before the late 20th century, overweight and obesity were not considered population-wide health risks, but the advent of weight loss drugs in the 1990s accelerated hypermedicalization via BMI use.
AMA J Ethics. 2023;25(7):E550-558. doi:
10.1001/amajethics.2023.550.
Decisions about where and to whose professional stewardship patients are admitted are influenced by federal policies of which physicians might not be aware.
AMA J Ethics. 2023;25(12):E901-908. doi:
10.1001/amajethics.2023.901.
A physician discusses the disparity of care for uninsured or underinsured cancer patients in terms of their time of diagnosis, treatment, and clinical outcomes.
Amy B. Cadwallader, PhD, Kavitha Nallathambi, MPH, MBA, and Carly Ching, PhD
Poor-quality antimicrobial medicines continue to proliferate across supply chains, threatening patients’ health and safety, especially in low- and middle-income regions.
AMA J Ethics. 2024;26(6):E472-478. doi:
10.1001/amajethics.2024.472.